Jing H. Wang, MD, PhD

  • Professor, Department of Medicine, Division of Hematology/Oncology

Education & Training

  • Postdoctoral Fellow, Children’s Hospital Boston and Harvard Medical School, Boston, MA, 2009
  • PhD in Immunology, University of Chicago, 2004
  • MS, Ohio State University, Columbus, OH, 1998
  • MD, Beijing Medical University (now known Peking University Health Science Center), 1996

Research Interests

The goals of my research program include: (1) define the cellular and molecular mechanisms of immune evasion during cancer development; (2) develop more effective cancer immunotherapy, with a focus on head and neck squamous cell carcinomas (HNSCCs) and B cell lymphomas; (3) elucidate the basic mechanisms of antibody gene diversification and B cell lymphomagenesis.


Woolaver RA, Wang X, Krinsky AL, Waschke BC, Chen SMY, Popolizio V, Nicklawsky AG, Gao D, Chen Z, Jimeno A, Wang XJ, Wang JH. Differences in TCR repertoire and T cell activation underlie the divergent outcomes of antitumor immune responses in tumor-eradicating versus tumor-progressing hosts. J Immunother Cancer. 2021 Jan;9(1):e001615. doi: 10.1136/jitc-2020-001615. PMID: 33414263

Chen Z*, Krinsky A, Woolaver RA, Wang X, Chen SMY, Popolizio V, Xie P, Wang JH*. TRAF3 Acts as a Checkpoint of B Cell Receptor Signaling to Control Antibody Class Switch Recombination and Anergy. Journal of Immunology. 2020 Aug 1; 205(3):830-841. PMID: 32591397; PMCID: PMC7369235. *co-senior authorship.

Wang X, Waschke BC, Woolaver RA, Chen SMY, Chen Z, Wang JH. MHC Class-I independent activation of virtual-memory CD8 T cells induced by chemotherapeutic agent-treated cancer cells. Cellular & Molecular Immunology. 2020 May 19. PMID: 32427883.

Wang X, Waschke BC, Woolaver RA, Chen Z, Zhang G, Piscopio AD, Liu X, Wang JH. Histone-deacetylase inhibition sensitizes PD1 blockade–resistant B-cell lymphomas. Cancer Immunology Research. 2019 Aug;7(8):1318-1331. PMID: 31235619.

Mishra AK, Kadoishi T, Wang X, Driver E, Chen Z, Wang XJ, Wang JH (2016). Squamous Cell Carcinomas Escape Immune Surveillance via Inducing Chronic Activation and Exhaustion of CD8+ T Cells co-expressing PD-1 and LAG-3 Inhibitory Receptors. Oncotarget, Vol. 7, (No. 49), pp: 81341-81356. PMCID: PMC5340255.

Click here for a full listing of publications>